EC 35 (Risedronate Sodium Delayed-Release 35 mg)
Pill with imprint EC 35 is Yellow, Capsule-shape and has been identified as Risedronate Sodium Delayed-Release 35 mg. It is supplied by Actavis.
Risedronate is used in the treatment of osteoporosis; paget's disease; prevention of osteoporosis and belongs to the drug class bisphosphonates. Risk cannot be ruled out during pregnancy. Risedronate 35 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for EC 35
Risedronate Sodium Delayed-Release
- Imprint
- EC 35
- Strength
- 35 mg
- Color
- Yellow
- Shape
- Capsule-shape
- Availability
- Prescription only
- Drug Class
- Bisphosphonates
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Actavis
- Inactive Ingredients
-
edetate disodium,
ferric oxide yellow,
magnesium stearate,
methacrylic acid - ethyl acrylate copolymer (1:1) type a,
polysorbate 80,
microcrystalline cellulose,
silicon dioxide,
sodium starch glycolate type A potato,
stearic acid,
magnesium silicate,
triethyl citrate
Note: Inactive ingredients may vary.
Labelers / Repackagers
| NDC Code | Labeler / Repackager |
|---|---|
| 00591-3876 (Discontinued) | Watson Pharmaceuticals, Inc. |
| 00430-0979 | Warner Chilcott |
Related Images for "EC 35"
More about risedronate
- Side effects
- Drug interactions
- Dosage information
- During pregnancy or Breastfeeding
- Reviews (63)
- Patient tips
- Drug images
- Pricing & coupons
- En español
- Drug class: bisphosphonates
Patient resources
- Drug Information
- Risedronate (Advanced Reading)
- Risedronate Delayed-Release Tablets
- Risedronate Tablets
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.